Open access
Open access
Powered by Google Translator Translator

Critical Care & Emergencies (All Articles)

Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

23 Jul, 2021 | 10:51h | UTC

Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet

Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

 


Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients.

23 Jul, 2021 | 10:47h | UTC

Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients – Intensive Care Medicine

 


Review: Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit.

23 Jul, 2021 | 10:30h | UTC

Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review – Critical Care

 


Review: Ethics in extracorporeal life support.

23 Jul, 2021 | 10:29h | UTC

Ethics in extracorporeal life support: a narrative review – Critical Care

 


Review: The routes of administration for acute postoperative pain medication.

22 Jul, 2021 | 10:46h | UTC

The Routes of Administration for Acute Postoperative Pain Medication – Pain and Therapy

 


Review: Personalized mechanical ventilation in acute respiratory distress syndrome.

22 Jul, 2021 | 10:40h | UTC

Personalized mechanical ventilation in acute respiratory distress syndrome – Critical Care

Related: M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies. AND Seminar | Acute respiratory distress syndrome. AND Short review: Diagnosis and management of acute respiratory distress syndrome

 


A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.

22 Jul, 2021 | 10:37h | UTC

A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia – Open Forum Infectious Diseases

 

Commentary on Twitter

 


RCT: Immediate oral refeeding in patients with mild and moderate acute pancreatitis.

22 Jul, 2021 | 10:32h | UTC

Immediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial) – Annals of Surgery (link to abstract – $ for full-text)

 


Cohort study: Sickle cell disorders and severe COVID-19 outcomes – “Our analysis estimated a 4-fold increased risk for COVID-19–related hospitalization and a 2.6-fold increased risk for COVID-19–related death for sickle cell disease”.

21 Jul, 2021 | 10:44h | UTC

Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine

 


Expert review | Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy.

21 Jul, 2021 | 10:37h | UTC

Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy – American Journal of Obstetrics & Gynecology

 

Commentary on Twitter

 


ICU Survivorship—The relationship of delirium, sedation, dementia, and acquired weakness.

21 Jul, 2021 | 10:32h | UTC

ICU Survivorship—The Relationship of Delirium, Sedation, Dementia, and Acquired Weakness – Critical Care Medicine

 


WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

20 Jul, 2021 | 10:29h | UTC

Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) – World Health Organization

Related Guidance: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” AND ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

 


WHO warns that HIV infection increases risk of severe and critical COVID-19.

20 Jul, 2021 | 10:24h | UTC

News release: WHO warns that HIV infection increases risk of severe and critical COVID-19 – World Health Organization

Report: WHO report on clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with SARS-CoV-2 infection

Related: M-A: Epidemiology and outcomes of COVID-19 in HIV-infected individuals – HIV is a significant risk factor for acquiring SARS-CoV-2 infection and is associated with a higher risk of mortality.

 

Commentary on Twitter (thread – click for more)

 


International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.

20 Jul, 2021 | 10:21h | UTC

Ischemic and Hemorrhagic Stroke Among Critically Ill Patients With Coronavirus Disease 2019: An International Multicenter Coronavirus Disease 2019 Critical Care Consortium Study – Critical Care Medicine

Related: SARS-CoV-2 and Stroke Characteristics – higher rate of large vessel occlusions and stroke in young patients AND Case series of 18 male adults aged 50 years or younger with acute ischemic stroke during the convalescent phase of asymptomatic Covid-19 AND Case-control study: COVID-19-associated stroke is associated with worse outcomes and increased mortality AND Pictorial essay: Neurological emergencies associated with COVID-19: stroke and beyond AND Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke AND Risk of Ischemic Stroke in Patients with COVID-19 vs. Patients with Influenza

 


RCT: more data showing Azithromycin is not better than placebo in patients with Covid-19.

18 Jul, 2021 | 23:54h | UTC

Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial – JAMA

Commentary: Common antibiotic no more effective than placebo in preventing COVID-19 symptoms among non-hospitalized – University of California – San Francisco

Related: RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19. (several articles on the subject)

 

Commentary on Twitter

 


Position Paper: Recommendations for the use of topical inhalant budesonide in COVID-19.

18 Jul, 2021 | 23:53h | UTC

Recommendations for use of topical inhalant budesonide in COVID-19 – HNO

Related: RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19 AND Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

 


Review: Acute kidney injury.

18 Jul, 2021 | 23:18h | UTC

Acute kidney injury – Nature Reviews Disease Primers (free for a limited period)

 

Commentary on Twitter

 


Why was a major study on ivermectin for covid-19 just retracted?

16 Jul, 2021 | 11:11h | UTC

Why Was a Major Study on Ivermectin for COVID-19 Just Retracted? – Grifter Analysis and Review

See also: Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns – The Guardian AND Some problems in the dataset of a large study of Ivermectin for the treatment of Covid-19 – Nick Brown’s Blog AND Is Ivermectin for Covid-19 Based on Fraudulent Research? – Gideon M-K; Health Nerd

 

Commentary on Twitter (thread – click for more)

 


Short review: The gut in COVID-19.

16 Jul, 2021 | 10:54h | UTC

The gut in COVID-19 – Intensive Care Medicine

 

Commentary on Twitter

 


Pathophysiology of COVID-19-associated acute kidney injury.

16 Jul, 2021 | 10:52h | UTC

Pathophysiology of COVID-19-associated acute kidney injury – Nature Reviews Nephrology

 


AAFP Guideline: Pharmacologic Management of COPD Exacerbations.

16 Jul, 2021 | 10:51h | UTC

Pharmacologic Management of COPD Exacerbations: A Clinical Practice Guideline from the AAFP – American Family Physician

 


M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies.

16 Jul, 2021 | 10:43h | UTC

Higher versus lower positive end-expiratory pressure in patients without acute respiratory distress syndrome: a meta-analysis of randomized controlled trials – Critical Care

 


Review: Sedation in the Intensive Care Unit.

16 Jul, 2021 | 10:31h | UTC

Sedation in the Intensive Care Unit – Current Anesthesiology Reports

 


RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).

15 Jul, 2021 | 09:26h | UTC

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 – New England Journal of Medicine

 


Tramadol: Where do we go from here? – “Tramadol’s unpredictability, unique potential harms, and lack of advantage over other opioids or NSAIDs are now well recognized”.

15 Jul, 2021 | 09:14h | UTC

[131] Tramadol: Where do we go from here? – Therapeutic Initiative

 


Stay Updated in Your Specialty

No spam, just news.